Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).
Guru Sonpavde
Research Funding - Sanofi
Menaka Bhor
No relevant relationships to disclose
Daniel Hennessy
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Debajyoti Bhowmik
Employment or Leadership Position - McKesson
Liji Shen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Other Remuneration - Sanofi
Ian D. Schnadig
No relevant relationships to disclose